AI analysis from Brainomix adds to evidence backing Endeavor's IPF therapy

Brainomix's AI-driven 360[e-Lung] CT analysis reveals that Endeavor BioMedicines' taladegib significantly improves lung volume and reduces fibrosis beyond standard lung function measures in IPF patients, supporting its continued clinical development.

This Wire brief sits within Fusion42's coverage of Digital Health, Biotech and AI Infrastructure.